Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01901224
Recruitment Status : Terminated (study was not funded)
First Posted : July 17, 2013
Results First Posted : September 24, 2018
Last Update Posted : September 24, 2018
Sponsor:
Information provided by (Responsible Party):
Mark Alan Creager, MD, Brigham and Women's Hospital

Brief Summary:

The investigators are doing this research study to find out if taking Metformin improves walking ability in patients with peripheral arterial disease (PAD). In PAD the arteries (blood vessels) in the legs are narrowed because of the build up of plaque. The leg muscle can hurt in patients with PAD and this is usually described as a cramp or tiredness. This pain is called intermittent claudication. Metformin is an FDA approved medication for the treatment of diabetes. The investigators believe that Metformin may help your leg muscles work better.

The investigators will enroll up to 100 subjects in order to find 60 subjects with PAD at Brigham and Women's Hospital (BWH).


Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Drug: Metformin 1000 mg Drug: Placebo Phase 4

Detailed Description:
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that affects more than 7 million adults in the US. The prevalence of PAD increases with age and is estimated to be 15 20% among individuals 65 years of age and older. Patients with PAD have limited functional capacity; they walk more slowly and have less walking endurance than persons who do not have PAD, irrespective of whether they have classic symptoms of intermittent claudication or critical limb ischemia. This functional impairment adversely affects quality of life. Although flow limitation due to atherosclerotic stenosis is necessary for the development of symptoms in PAD, the lack of correlation between walking capacity and the degree of hemodynamic compromise raises the possibility that alternative mechanisms contribute to functional limitations in these patients. Putative mechanisms include inadequate skeletal muscle glucose uptake, altered skeletal muscle energetics, and impaired vasomotor tone and nutrient delivery mediated by endothelial dysfunction. Metformin, via AMPactivated protein kinase (AMPK)-dependent and independent mechanisms, can favorably affect skeletal muscle metabolic functions including glucose uptake, fatty acid oxidation, mitochondrial function, and consequently cellular energetics, and it also may have a direct salutary effect on vascular function via regulation of nitric oxide synthase. It is intriguing, therefore, to consider the possibility that metformin would improve skeletal muscle metabolic and vascular function in older patients with PAD and translate into functional benefits. Accordingly, the investigators seek to elucidate molecular mechanisms through which metformin affects skeletal muscle energetics and hypothesize that metformin will lead to advantageous metabolic, vascular, and physical functional changes in older patients with PAD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease
Study Start Date : July 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Metformin 1000 mg
metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
Drug: Metformin 1000 mg
Placebo Comparator: Control
placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
Drug: Placebo



Primary Outcome Measures :
  1. Change in PCr Recovery Time [ Time Frame: baseline, 12 weeks ]
    PCr recovery time, measured in seconds, is a measure of skeletal muscle metabolic function. PCr is a transport molecule and reservoir of high-energy phosphate bonds, which is important for cellular energetics. Phosphocreatine regeneration depends upon the skeletal muscle mitochondrial cells capacity for oxidative phosphorylation. We will measure PCr recovery time at baseline and after 12 weeks of treatment with metformin or placebo as an in vivo measure of mitochondrial function. Higher Pcr relative to P(i) during recovery is better and shorter recovery times are better.


Secondary Outcome Measures :
  1. Change in Flow-mediated Dilation (FMD) [ Time Frame: baseline, 12 weeks ]
    Flow mediated vasodilation of the brachial artery is a measure of endothelium-dependent vasodilation. Higher flow-mediated dilation (FMD), measured as the diameter of the brachial artery in millimeters, and reported as percent change after a flow stimulus compered to basal measurement, is better, indicative of better endothelial function.


Other Outcome Measures:
  1. Change in Maximal Treadmill Walking Time [ Time Frame: baseline, 12 weeks ]
    Maximal treadmill walking time is measured in minutes or seconds. Higher values indicate a better outcome.

  2. Change in Pain-free Treadmill Walking Time [ Time Frame: baseline, 12 weeks ]
    Pain-free treadmill walking time is measured in minutes or seconds. Higher values indicate a better outcome.

  3. Change in Oxygen Consumption [ Time Frame: baseline, 12 weeks ]
    Oxygen consumption is measured in ml/kg/min. Higher values indicate better outcomes.

  4. Change in Six Minute Walk Test [ Time Frame: baseline, 12 weeks ]
    The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes.The 6 MWT is measured in meters, and higher values indicate better outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 40 years or greater
  • Intermittent claudication for 6 months or greater
  • Maximal walk time between 1-20 minutes on all ETTs
  • Resting ABI ≤ 0.9 in index leg at baseline
  • ABI falls ≥ 20% in index leg 1 minute post baseline ETT
  • MWT variability < 20%

Exclusion Criteria:

  • Type 1 or Type 2 Diabetes
  • Limb-threatening ischemia (rest pain, ulceration, gangrene)
  • Peripheral vascular surgery or PCI within 6 months
  • MI or CABG within 6 months
  • Carotid endarterectomy (CEA) within 6 months
  • Cerebrovascular accident or TIA within 6 months
  • Uncontrolled hypertension (SBP > 140 mmHg, DBP >90 mmHg)
  • Pentoxifylline/Cilostazol added/changed within 3 months
  • HMG-CoA reductase inhibitor added/changed within 3 months
  • Exercise limitations other than claudication (heart failure, angina, COPD, arthritis, neuropathy, etc.)
  • Serum creatinine ≥ 1.5 mg/dL
  • Pregnant or plans to become pregnant
  • 2 hour Oral Glucose Tolerance Test (OGTT) > 200 mg/dL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01901224


Locations
Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Mark A Creager, MD Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Mark Alan Creager, MD, Mark A. Creager, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01901224    
Other Study ID Numbers: 2013P001042
First Posted: July 17, 2013    Key Record Dates
Results First Posted: September 24, 2018
Last Update Posted: September 24, 2018
Last Verified: September 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs